Download PDF
Thromb Haemost 2014; 111(06): 1167-1176
DOI: 10.1160/TH14-03-0231
New Technologies, Diagnostic Tools and Drugs
Schattauer GmbH

Feasibility and cost-effectiveness of stroke prevention through community screening for atrial fibrillation using iPhone ECG in pharmacies

The SEARCH-AF study
Nicole Lowres
1   Cardiology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia
2   Anzac Research Institute, Sydney, New South Wales, Australia
3   Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
,
Lis Neubeck
4   The George Institute for Global Health, Sydney, New South Wales, Australia
5   Sydney Nursing School, University of Sydney, Sydney, New South Wales, Australia
,
Glenn Salkeld
6   School of Public Health, University of Sydney, Sydney, New South Wales, Australia
,
Ines Krass
7   Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
,
Andrew J. McLachlan
7   Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
8   Centre for Education and Research on Aging, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
,
Julie Redfern
3   Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
4   The George Institute for Global Health, Sydney, New South Wales, Australia
,
Alexandra A. Bennett
7   Faculty of Pharmacy, University of Sydney, Sydney, New South Wales, Australia
8   Centre for Education and Research on Aging, Concord Repatriation General Hospital, Sydney, New South Wales, Australia
,
Tom Briffa
9   School of Population Health, University of Western Australia, Perth, Western Australia, Australia
,
Adrian Bauman
6   School of Public Health, University of Sydney, Sydney, New South Wales, Australia
,
Carlos Martinez
10   Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
,
Christopher Wallenhorst
10   Institute for Epidemiology, Statistics and Informatics GmbH, Frankfurt, Germany
,
Jerrett K. Lau
1   Cardiology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia
,
David B. Brieger
1   Cardiology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia
2   Anzac Research Institute, Sydney, New South Wales, Australia
3   Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
,
Raymond W. Sy
1   Cardiology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia
2   Anzac Research Institute, Sydney, New South Wales, Australia
3   Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
,
S. Ben Freedman
1   Cardiology Department, Concord Repatriation General Hospital, University of Sydney, Sydney, New South Wales, Australia
2   Anzac Research Institute, Sydney, New South Wales, Australia
3   Sydney Medical School, University of Sydney, Sydney, New South Wales, Australia
› Author Affiliations Financial support: The screening study was supported by an investigator-initiated grant from Bristol-Myers Squibb/Pfizer, and a small investigator-initiated project award from Boehringer Ingelheim. Cost-effectiveness analysis was supported by an investigator-initiated grant from Bayer. AliveCor provided ECG Heart Monitors for study purposes. The investigators are not affiliated with, nor have any financial or other interest in AliveCor. Dr Redfern is funded by a Career Development and Future Leader Fellowship cofunded by the NHMRC and National Heart Foundation (APP1061793). Dr Neubeck is an NHMRC early career fellow (APP1036763). Ms Lowres is funded by a National Heart Foundation Postgraduate Scholarship (PP12S6990).
Further Information

Publication History

Received: 13 March 2014

Accepted after minor revision: 18 March 2014

Publication Date:
21 November 2017 (online)

Also available at
    Permissions and Reprints

Summary

Atrial fibrillation (AF) causes a third of all strokes, but often goes undetected before stroke. Identification of unknown AF in the community and subsequent anti-thrombotic treatment could reduce stroke burden. We investigated community screening for unknown AF using an iPhone electrocardiogram (iECG) in pharmacies, and determined the cost-effectiveness of this strategy. Pharmacists performed pulse palpation and iECG recordings, with cardiologist iECG over-reading. General practitioner review/12-lead ECG was facilitated for suspected new AF. An automated AF algorithm was retrospectively applied to collected iECGs. Cost-effectiveness analysis incorporated costs of iECG screening, and treatment/outcome data from a United Kingdom cohort of 5,555 patients with incidentally detected asymptomatic AF. A total of 1,000 pharmacy customers aged ≥65 years (mean 76 ± 7 years; 44% male) were screened. Newly identified AF was found in 1.5% (95% CI, 0.8–2.5%); mean age 79 ± 6 years; all had CHA2DS2-VASc score ≥2. AF prevalence was 6.7% (67/1,000). The automated iECG algorithm showed 98.5% (CI, 92–100%) sensitivity for AF detection and 91.4% (CI, 89–93%) specificity. The incremental cost-effectiveness ratio of extending iECG screening into the community, based on 55% warfarin prescription adherence, would be $AUD5,988 (€3,142; $USD4,066) per Quality Adjusted Life Year gained and $AUD30,481 (€15,993; $USD20,695) for preventing one stroke. Sensitivity analysis indicated cost-effectiveness improved with increased treatment adherence. Screening with iECG in pharmacies with an automated algorithm is both feasible and cost-effective. The high and largely preventable stroke/thromboembolism risk of those with newly identified AF highlights the likely benefits of community AF screening. Guideline recommendation of community iECG AF screening should be considered.

Previous Presentation: This study was presented in part as an oral presentation at the Cardiac Society of Australia and New Zealand Conference; 9 August 2013; Sydney, Australia, abstract published in Heart Lung Circulation 2013;22:S223.

Trial registration: Australian New Zealand clinical trials registry: ACTRN12612000406808.

Keywords

Atrial fibrillation - screening - stroke prevention - cost-effectiveness - anticoagulation

 

  • References

  • 1 Leyden JM, Kleinig TJ, Newbury J. et al. Adelaide stroke incidence study: declining stroke rates but many preventable cardioembolic strokes. Stroke 2013; 44: 1226-1231.
    CrossrefPubMedGoogle Scholar
  • 2 Björck S, Palaszewski B, Friberg L. et al. Atrial fibrillation, stroke risk, and warfarin therapy revisited: A population-based study. Stroke 2013; 44: 3103-3108.
    CrossrefPubMedGoogle Scholar
  • 3 Hart RG, Pearce LA, Aguilar MI. Meta-analysis: Antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146: 857-867.
    CrossrefPubMedGoogle Scholar
  • 4 Deif B, Lowres N, Freedman SB. Screening for atrial fibrillation above age 65 detects an asymptomatic subset at high risk of stroke. Int J Cardiol 2013; 164: 371-372.
    CrossrefPubMedGoogle Scholar
  • 5 Healey JS, Connolly SJ, Gold MR. et al. Subclinical atrial fibrillation and the risk of stroke. N Engl J Med 2012; 366: 120-129.
    CrossrefPubMedGoogle Scholar
  • 6 Tsang TS, Barnes ME, Pellikka PA. et al. Silent atrial fibrillation in Olmsted County: A community-based study. Can J Cardiol 2011; 27: S122.
    CrossrefPubMedGoogle Scholar
  • 7 Marini C, De Santis F, Sacco S. et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke 2005; 36: 1115-1119.
    CrossrefPubMedGoogle Scholar
  • 8 Kimura K, Minematsu K, Yamaguchi T. Atrial fibrillation as a predictive factor for severe stroke and early death in 15 831 patients with acute ischaemic stroke. J Neurol Neurosurg Psychiatry 2005; 76: 679-683.
    CrossrefPubMedGoogle Scholar
  • 9 Jorgensen HS, Nakayama H, Reith J. et al. Acute stroke with atrial fibrillation. The Copenhagen stroke study. Stroke 1996; 27: 1765-1769.
    CrossrefPubMedGoogle Scholar
  • 10 Camm AJ, Lip GYH, Caterina RD. et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation. An update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-2747.
    CrossrefPubMedGoogle Scholar
  • 11 Stott DJ, Dewar RI, Garratt CJ. et al. RCPE UK consensus conference on ‘ap-proaching the comprehensive management of atrial fibrillation: evolution or revolution?’. J R Coll Physicians Edinb 2012; 42: 3-4.
    CrossrefPubMedGoogle Scholar
  • 12 National Collaborating Centre for Chronic Conditions. Atrial fibrillation: national clinical guideline for management in primary and secondary care. 2006. London: Royal College of Physicians;
    Google Scholar
  • 13 Anderson JL, Halperin JL, Albert NM. et al. Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): A report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2013; 127: 1916-1926.
    CrossrefPubMedGoogle Scholar
  • 14 Lowres N, Neubeck L, Redfern J. et al. Screening to identify unknown atrial fibrillation: A systematic review. Thromb Haemost 2013; 110: 213-222.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 15 Engdahl J, Andersson L, Mirskaya M. et al. Stepwise screening of atrial fibrillation in a 75-year old population: implications for stroke prevention. Circulation 2013; 127: 930-937.
    CrossrefPubMedGoogle Scholar
  • 16 Chapman CB, Marriott JL, van den Bosch D. The nature, extent and impact of triage provided by community pharmacy in Victoria. Pharmacy Guild of Australia. 2010 Accessed 15 June 2013 from: http://www.guild.org.au/docs/default-source/public-documents/services-and-programs/research-and-development/Fourth-Agreement-R-and-D/IIG-008/full-final-report-.pdf?sfvrsn=0
    PubMedGoogle Scholar
  • 17 Benrimoj SI, Frommer MS. Community pharmacy in Australia. Aust Health Rev 2004; 28: 238-246.
    CrossrefPubMedGoogle Scholar
  • 18 Krass I, Mitchell B, Clarke P. et al. Pharmacy diabetes care program: analysis of two screening methods for undiagnosed type 2 diabetes in Australian community pharmacy. Diabetes Res Clin Pract 2007; 75: 339-347.
    CrossrefPubMedGoogle Scholar
  • 19 Baraitser P, Pearce V, Holmes J. et al. Chlamydia testing in community pharmacies: evaluation of a feasibility pilot in south east London. Qual Saf Health Care 2007; 16: 303-307.
    CrossrefPubMedGoogle Scholar
  • 20 Lau JK, Lowres N, Neubeck L. et al. iPhone ECG application for community screening to detect silent atrial fibrillation: A novel technology to prevent stroke. Int J Cardiol 2013; 165: 193-194.
    CrossrefPubMedGoogle Scholar
  • 21 Lowres N, Freedman SB, Redfern J. et al. Screening Education And Recognition in Community pHarmacies of Atrial Fibrillation to prevent stroke in an ambulant population aged ≥65 years (SEARCH-AF stroke prevention study): a cross-sectional study protocol. Br Med J Open 2012; 2.
    PubMedGoogle Scholar
  • 22 Organisation for economic co-operation and development. Purchasing power parities. Accessed 14 March 2014 from: http://stats.oecd.org/Index.aspx?data-setcode=SNA_TABLE4
    PubMedGoogle Scholar
  • 23 Freedman SB, Katholing A, Martinez C. Adverse prognosis of asymptomatic atrial fibrillation detected incidentally: a case for screening. J Am Coll Cardiol 2013; 61: E371.
    CrossrefPubMedGoogle Scholar
  • 24 Tsadok MA, Jackevicius CA, Rahme E. et al. Sex Differences in Stroke Risk Among Older Patients With Recently Diagnosed Atrial Fibrillation. J Am Med Assoc 2012; 307: 1952-1958.
    CrossrefPubMedGoogle Scholar
  • 25 Cadilhac DA, Dewey HM, Vos T. et al. The health loss from ischemic stroke and intracerebral hemorrhage: evidence from the North East Melbourne Stroke Incidence Study (NEMESIS). Health Qual Life Outcomes 2010; 08: 49.
    CrossrefPubMedGoogle Scholar
  • 26 Briggs AH. Statistical approaches to handling uncertainty in health economic evaluation. Eur J Gastroenterol Hepatol 2004; 16: 551-561.
    CrossrefPubMedGoogle Scholar
  • 27 Connolly SJ, Ezekowitz MD, Yusuf S. et al. Dabigatran versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2009; 361: 1139-1151.
    CrossrefPubMedGoogle Scholar
  • 28 Granger CB, Alexander JH, McMurray JJV. et al. Apixaban versus Warfarin in Patients with Atrial Fibrillation. N Engl J Med 2011; 365: 981-992.
    CrossrefPubMedGoogle Scholar
  • 29 Pisters R, Nieuwlaat R, Lane DA. et al. Potential net clinical benefit of population-wide implementation of apixaban and dabigatran among European patients with atrial fibrillation. A modelling analysis from the Euro Heart Survey. Thromb Haemost 2013; 109: 328-336.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 30 Giugliano RP, Ruff CT, Braunwald E. et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104.
    CrossrefPubMedGoogle Scholar
  • 31 Moran PS, Flattery MJ, Teljeur C. et al. Effectiveness of systematic screening for the detection of atrial fibrillation. Cochrane Database Syst Rev [Internet]. 2013 04. CD009586 Available from: http://onlinelibrary.wiley.com/ doi/10.1002/14651858.CD009586.pub2/abstract
    PubMedGoogle Scholar
  • 32 Hobbs FDR, Fitzmaurice DA, Mant J. et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over. The SAFE study. Health Technol Assess. 2005 09. ii-iv ix-x, 1–74
    PubMedGoogle Scholar
  • 33 Claes N, Van Laethem C, Goethals M. et al. Prevalence of atrial fibrillation in adults participating in a large-scale voluntary screening programme in Belgium. Acta Cardiol 2012; 67: 273-278.
    CrossrefPubMedGoogle Scholar
  • 34 Carrington M, Jennings G, Clark R. et al. Assessing cardiovascular risk in regional areas: the healthy hearts - beyond city limits program. BMC Health Serv Res 2012; 12: 296.
    CrossrefPubMedGoogle Scholar
  • 35 Rawlins MD, Culyer AJ. National Institute for Clinical Excellence and its value judgments. Br Med J 2004; 329: 224-227.
    CrossrefPubMedGoogle Scholar
  • 36 Vestergaard AS. A health economic evaluation of stroke prevention in atrial fibrillation – current treatment practice versus guideline adherence in Denmark [Masters Thesis]. 2013. Aalborg University;
    Google Scholar
  • 37 Zalesak M, Siu K, Francis K. et al. Higher persistence in newly diagnosed non-valvular atrial fibrillation patients treated with dabigatran versus warfarin. Circulation: Cardiovasc Qual Outcomes 2013; 06: 567-574.
    PubMedGoogle Scholar
  • 38 Banerjee A, Lane DA, Torp-Pedersen C. et al. Net clinical benefit of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus no treatment in a ‘real world’ atrial fibrillation population: A modelling analysis based on a nationwide cohort study. Thromb Haemost 2012; 107: 584-589.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 39 LaHaye S, Regpala S, Lacombe S. et al. Evaluation of patients’ attitudes towards stroke prevention and bleeding risk in atrial fibrillation. Thromb Haemost 2014; 111: 465-473.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 40 Lane DA, Lip GYH. Patient’s values and preferences for stroke prevention in atrial fibrillation: balancing stroke and bleeding risk with oral anticoagulation. Thromb Haemost 2014; 111: 381-383.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 41 Pink J, Lane S, Pirmohamed M. et al. Dabigatran etexilate versus warfarin in management of non-valvular atrial fibrillation in UK context: quantitative benefit-harm and economic analyses. Br Med J 2011; 343: d6333.
    CrossrefPubMedGoogle Scholar
  • 42 Kansal AR, Sharma M, Bradley-Kennedy C. et al. Dabigatran versus rivaroxaban for the prevention of stroke and systemic embolism in atrial fibrillation in Canada. Comparative efficacy and cost-effectiveness. Thromb Haemost 2012; 108: 672-682.
    Article in Thieme ConnectPubMedGoogle Scholar
  • 43 SPEAK about AF Survey (2011) – ISBN978–3–9814382–0–8. Accessed 08 July 2013 from: http://speakaf.com/_media/downloads/brochure.pdf
    PubMed
  • 44 Aliot E, Breithardt G, Brugada J. et al. An international survey of physician and patient understanding, perception, and attitudes to atrial fibrillation and its contribution to cardiovascular disease morbidity and mortality. Europace 2010; 12: 626-633.
    CrossrefPubMedGoogle Scholar
  • 45 American Heart Association. Half of those with atrial fibrillation don’t know of increased stroke risk, survey finds. Accessed 08 July 2013 from: http://news-room.heart.org/news/half-of-those-with-atrial-fibrillation-215647
    PubMedGoogle Scholar
  • 46 Lip GYH, Kamath S, Jafri M. et al. Ethnic differences in patient perceptions of atrial fibrillation and anticoagulation therapy: the West Birmingham Atrial Fibrillation Project. Stroke 2002; 33: 238-242.
    CrossrefPubMedGoogle Scholar
  • 47 Lee VWY, Tam CS, Yan BP. et al. Barriers to warfarin use for stroke prevention in patients with atrial fibrillation in Hong Kong. Clin Cardiol 2013; 36: 166-171.
    CrossrefPubMedGoogle Scholar
  • 48 Ovbiagele B, Goldstein LB, Higashida RT. et al. Forecasting the future of stroke in the United States: a policy statement from the american heart association and american stroke association. Stroke 2013; 44: 2361-2375.
    CrossrefPubMedGoogle Scholar
  • 49 Neubeck L, Orchard J, Freedman SB. Fog on the crystal ball? Missing atrial fibrillation in forecasting the future of stroke. Stroke 2013; 44: e136.
    CrossrefPubMedGoogle Scholar